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OBJECTIVES We sought to determine the effectiveness of primary angioplasty compared with thrombolysis
in clinical practice.
BACKGROUND In clinical practice, primary angioplasty for the treatment of acute myocardial infarction
(AMI) has not yet been proven more effective than intravenous thrombolysis, nor have
subgroups of patients been identified who would perhaps benefit from primary angioplasty.
METHODS The pooled data of two AMI registries—the Maximal Individual TheRapy in Acute
myocardial infarction (MITRA) study and the Myocardial Infarction Registry (MIR)—were
analyzed. A total of 9,906 lytic-eligible patients with AMI, with a pre-hospital delay of
#12 h, were treated with either primary angioplasty (n 5 1,327) or thrombolysis (n 5 8,579).
RESULTS Despite differences in the patients’ characteristics and concomitant diseases between the two
groups, the prevalence of adverse risk factors was balanced. Univariate analysis of hospital
mortality showed a more favorable course for patients treated with primary angioplasty: 6.4%
versus 11.3% (odds ratio [OR] 0.54, 95% confidence interval [CI] 0.43 to 0.67). This was
confirmed by logistic regression analysis (multivariate OR 0.58, 95% CI 0.44 to 0.77).
Primary angioplasty was associated with a lower mortality in all subgroups analyzed. We
observed a significant correlation between mortality and absolute risk reduction (r 5 0.82,
p , 0.0001) in the different subgroups: as mortality increased, there was an increase in
absolute benefit of primary angioplasty compared with thrombolysis.
CONCLUSIONS These large registry data showed the effect of primary angioplasty to be more favorable than
thrombolysis for the treatment of patients with AMI in clinical practice. This effect was not
restricted to special subgroups of patients. As mortality increased, the absolute benefit of
primary angioplasty also increased. (J Am Coll Cardiol 2001;37:1827–35) © 2001 by the
American College of Cardiology
Primary percutaneous transluminal coronary angioplasty—
that is, angioplasty without preceding or concomitant
thrombolysis—was introduced for the treatment of patients
See page 1836
with acute myocardial infarction (AMI) in 1982 and 1983
by Meyer et al. (1) and Hartzler et al. (2). During the
following 15 years, a series of predominantly small, prospec-
tive, randomized trials comparing primary angioplasty with
intravenous thrombolysis has been published (3–8). Meta-
analysis of these randomized studies showed a superiority of
primary angioplasty over thrombolysis in terms of hospital
mortality (9).
However, there was concern whether these results, from
highly specialized centers treating selected patients, could be
transferred into clinical practice. This is especially true, as
the largest randomized study—the Global Use of Strategies
To Open occluded arteries in acute coronary syndromes
(GUSTO IIb) angioplasty substudy (8)—showed only a
moderate, nonsignificant reduction in hospital mortality for
patients treated with primary angioplasty. Also, three myo-
cardial infarction (MI) registries—the Myocardial Infarc-
tion Triage Investigators (MITI) Registry (10), the Na-
tional Registry of Myocardial Infarction-2 (NRMI-2) (11)
From the *Department of Cardiology, Herzzentrum Ludwigshafen, Ludwigshafen;
†Johannes Gutenberg Universita¨t, Mainz; ‡Klinikum Nu¨rnberg, Nu¨rnberg; §Univer-
sita¨tskliniken Homburg/Saar, Homburg; \Klinikum Friedrichstadt, Dresden; and
¶Sta¨dtisches Klinikum, Dessau, Germany. The individuals and institutions that
participated in the MITRA and MIR studies are listed elsewhere (see references 19
and 20). This study was supported in part by AstraZeneca, Bristol Myers-Squibb,
Ministerium fu¨r Gesundheit, Arbeit, Soziales des Landes Rheinland-Pfalz, Landes-
versicherungsanstalt Rheinland-Pfalz, Barmer and Betriebskrankenkassen Rheinland-
Pfalz.
Manuscript received September 8, 2000; revised manuscript received December 13,
2000, accepted February 13, 2001.
Journal of the American College of Cardiology Vol. 37, No. 7, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01264-5
and a French registry (12)—failed to show an advantage of
primary angioplasty over thrombolysis in the “real world.”
For these reasons, primary angioplasty is currently
judged, according to official recommendations, to be an
alternative to thrombolysis (13,14). Efforts have been made
to define subgroups of patients with AMI benefiting most
from primary angioplasty. However, these studies did not
systematically investigate different subgroups, and they also
showed divergent results. In some studies, primary angio-
plasty was superior to thrombolysis only in high-risk pa-
tients (6,15,16), whereas other studies showed a superiority
of primary angioplasty in low-risk patients (17). Therefore,
with the exception of patients in cardiogenic shock, no
general recommendation exists regarding which subgroups
of thrombolytic-eligible patients with AMI should be
treated with primary angioplasty (18).
To determine the value of primary angioplasty compared
with intravenous thrombolysis in different subgroups of
patients, we analyzed the pooled data of two German AMI
registries—the Maximal Individual TheRapy in Acute myo-
cardial infarction (MITRA) (19) study and the Myocardial
Infarction Registry (MIR) (20).
METHODS
The MITRA and MIR registries were both German,
prospective, multicenter, observational studies of the treat-
ment of patients with AMI. Both studies sought to treat
more AMI patients with established, prognostically impor-
tant and recommended therapies. The MITRA study
started in 1994 and ended 1997. Fifty-four hospitals par-
ticipated in the study. The MIR study was a nationwide
registry that included patients from 1996 to 1998. A total of
217 hospitals (mainly community hospitals) participated in
MIR. The protocols of both studies were almost identical.
Therefore, we used the pooled data from both studies for
this analysis. All patients presenting within the first 96 h of
the onset of pain were registered prospectively, as soon as
the diagnosis of AMI had been made.
Reperfusion therapy. The following protocols for intrave-
nous thrombolysis were suggested: intravenous application
of 1.5 million units of streptokinase over 1 h, or tissue
plasminogen activator (t-PA) at a dose of 100 mg over 1.5 h
intravenously. Angioplasty was performed according to the
standard protocol of each center. Angioplasty facilities were
available at 8 (14.8%) of 54 hospitals participating in
MITRA and 42 (19.4%) of 217 MIR centers. The decision
regarding the type of treatment was left to the discretion of the
treating physician, rather than according to the study protocol.
Definitions. Acute myocardial infarction was diagnosed
when the two following criteria were present: 1) persistent
angina pectoris lasting $20 min and ST segment elevation
$1 mm in at least two standard leads, or $2 mm in at least
two contiguous precordial leads; or 2) left bundle branch
block. It was later confirmed by cardiac enzyme elevation of
more than twice as high as the normal upper range.
“Pre-hospital delay” was defined as the time from the onset
of symptoms to hospital admission. “In-hospital time to
treatment” was defined as the time from admission to the
start of primary angioplasty (angiographic needle entry) or
the start of infusion of the thrombolytic agent. “Stroke” was
defined as a new, persistent cerebral deficiency after hospital
admission. Hemorrhagic stroke was not differentiated from
nonhemorrhagic stroke or stroke of unknown etiology. A
combined clinical end point was determined by the occur-
rence of death, re-infarction or stroke.
In this analysis, only lytic-eligible patients—that is, pa-
tients without contraindications to thrombolysis, treated
with either primary angioplasty or intravenous thrombolysis,
with a pre-hospital delay of #12 h—were included. Con-
traindications to thrombolysis consisted of stroke within the
last three months, surgery or trauma within the last 14 days
or active bleeding.
Statistics. DATA COLLECTION. Data on the pre-hospital
period and the early intra-hospital period (48 h) were
collected within the first two to three days of the patients’
stay in the intensive care unit. Clinical events that occurred
during the following hospital period were reported on a
separate record form at hospital discharge. Every participating
center was committed, during the study period, to include in
the study each AMI patient who gave written consent. The
patients also gave informed consent for processing of their
anonymous data. All data sheets were sent to the central data
processing center (Department of Cardiology, Herzzentrum
Ludwigshafen) for uniform monitoring and registration.
DATA ANALYSIS. Absolute numbers and percentages are
used to describe the patient population. Median or mean
values were computed, as appropriate. Categorical values
were compared by chi-square analysis or the Fisher exact
test, as appropriate, and the odds ratio (OR) and 95%
confidence interval (CI) were computed. Continuous vari-
ables were compared by the two-tailed Wilcoxon rank-sum
test. Logistic regression analysis was used to analyze the two
types of reperfusion therapy. The following variables were
examined: availability of angioplasty facilities, age, gender,
location of infarction, cardiogenic shock, previous MI,
Abbreviations and Acronyms
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resuscitation, heart failure at hospital admission, pre-
hospital delay, renal failure at admission, history of arterial
hypertension, and presence of a diagnostic first electrocar-
diogram (ECG). Logistic regression analyses were also used
to adjust for factors influencing hospital mortality for the
entire group and for subgroups. The following variables
were examined: age, gender, location of infarction, cardio-
genic shock, previous MI, resuscitation, heart failure at
hospital admission, pre-hospital delay, type of revascular-
ization, and concomitant therapy with beta-blockers and
angiotensin-converting enzyme (ACE) inhibitors. Data on
the prevalence of left or right bundle branch block were
available only in the MITRA registry. Therefore, these
variables were not included in the multiple logistic regres-
sion model. A further logistic regression analysis was done
to compare the primary angioplasty group with the group
treated with t-PA as the thrombolytic agent. We used the C
statistic to determine the predictive value of each adjusted
model. To analyze the effect of primary angioplasty com-
pared with thrombolysis on mortality in different subgroups,
the absolute risk reduction (ARR [%] 5 T death rate 2 PA
death rate), the relative risk (RR 5 PA death rate/T death
rate) (where T 5 thrombolysis and PA 5 primary angio-
plasty) and the number that needed to be treated to save one
life (NNT 5 100/ARR [%]) were calculated. Pearson’s
correlation coefficient was used to calculate the relationship
between RR and ARR and mortality in the subgroups. P
values ,0.05 were considered significant. All p values are
the results of two-tailed tests. The tests were performed
using the SAS statistical package, version 6.12 (Cary, North
Carolina).
RESULTS
Selection and characteristics of patients. The selection of
patients from the MITRA and MIR registries is shown in
Figure 1. Of 22,749 patients included in both registries,
9,906 lytic-eligible patients with a pre-hospital delay of
#12 h were treated with either primary angioplasty or
thrombolysis. Of the 1,327 patients treated with primary
angioplasty, 240 (18.1%) were transferred from other hos-
pitals. Of the 8,579 patients treated with thrombolysis,
4,295 (50%) received streptokinase; 2,369 (27.6%) received
t-PA; 1,423 (16.6%) received other thrombolytic agents;
and 492 (5.7%) had no available data on the type of
thrombolytic agent.
The patients’ characteristics and concomitant diseases are
shown in Table 1. The prevalence of adverse risk factors
Figure 1. Selection of patients from the MITRA and MIR trials.
Table 1. Baseline Characteristics and Concomitant Diseases
Primary
Angioplasty Group
(n 5 1,327)
Thrombolysis
Group
(n 5 8,579)
p
Value
Age (yrs) 62 (54/70) 64 (55/72) 0.006
Male gender 987/1,324 (74.6%) 6,136/8,556 (71.7%) 0.033
Anterior wall infarction 596/1,272 (46.9%) 3,948/8,367 (47.2%) 0.724
Previous MI 229/1,325 (17.3%) 1,207/8,569 (14.1%) 0.002
Cardiogenic shock 67/1,281 (5.2%) 313/7,985 (3.9%) 0.028
Heart failure at admission 36/1,325 (2.7%) 444/8,569 (5.2%) , 0.001
Resuscitation 87/1,281 (6.8%) 570/7,985 (7.1%) 0.653
Left bundle branch block* 10/465 (2.2%) 97/2,765 (3.5%) 0.134
Right bundle branch block* 18/465 (3.9%) 98/2,765 (3.5%) 0.726
Diagnostic first electrocardiogram 980/1,239 (79.1%) 7,055/8,125 (86.8%) , 0.001
Systolic blood pressure (mm Hg) 140 (120/160) 140 (120/160) 0.633
Heart rate (beats/min) 78 (66/90) 78 (64/90) 0.343
Pre-hospital delay (min) 150 (90/300) 120 (75/210) , 0.001
In-hospital time to treatment (min) 70 (45/132) 30 (17/55) , 0.001
Concomitant diseases
Renal failure 33/1,325 (2.5%) 114/8,569 (1.3%) , 0.001
Chronic obstructive pulmonary disease 33/1,325 (2.5%) 228/8,569 (2.7%) 0.719
Arterial hypertension 528/1,281 (41.2%) 2,830/7,985 (35.4%) , 0.001
Diabetes mellitus 238/1,281 (18.6%) 1,454/7,985 (18.2%) 0.750
*Data only available from the MITRA registry. Data are presented as the median value (quartiles) or number (%) of patients.
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seemed to be balanced between the two groups. Patients
treated with primary angioplasty were significantly younger
(median 62 vs. 64 years old, p 5 0.006), were more often
male (74.6% vs. 71.7%, p 5 0.033) and showed heart failure
less often at hospital admission (2.7% vs. 5.2%, p , 0.001).
However, they more often had previous MIs (17.3% vs.
14.1%, p , 0.002), a higher prevalence of renal failure
(2.5% vs. 1.3%, p , 0.001) and a history of arterial
hypertension (41.2% vs. 35.4%, p , 0.001). The pre-
hospital delay (median 150 vs. 120 min, p , 0.001) and the
in-hospital time to treatment (median 70 vs. 30 min, p ,
0.001) were longer in the primary angioplasty group.
Selection of reperfusion therapy. Logistic regression anal-
ysis showed the availability of angioplasty facilities to be the
strongest independent predictor of the use of primary
angioplasty (OR 24.18, 95% CI 20.50 to 28.65). A pre-
hospital delay .6 h (OR 2.67, 95% CI 2.07 to 3.43), a
nondiagnostic first ECG (OR 2.11, 95% CI 1.72 to 2.58),
cardiogenic shock (OR 1.70, 95% CI 1.16 to 2.47) and a
history of arterial hypertension (OR 1.39, 95% CI 1.19 to
1.62) were independently associated with a higher rate,
whereas the presence of heart failure at hospital admission
was associated with a lower rate (OR 0.46, 95% CI 0.29 to
0.70) of primary angioplasty compared with thrombolysis.
No independent association with the use of primary angio-
plasty was found for age, gender, location of infarction,
previous MI, renal failure or resuscitation.
Concomitant medications and clinical events. Patients
treated with primary angioplasty more often received aspi-
rin, heparin, beta-blockers and ACE inhibitors during the
first 48 h after hospital admission (Table 2).
Univariate analysis of clinical events showed a more
favorable course for patients treated with primary angio-
plasty compared with thrombolysis (re-infarction: 2.3% vs.
5.2%, OR 0.43, 95% CI 0.30 to 0.63; hospital mortality:
6.4% vs. 11.3%, OR 0.54, 95% CI 0.43 to 0.67; and the
combined end point of death, re-infarction or stroke: 9.1%
vs. 15.8%, OR 0.54, 95% CI 0.44 to 0.65) (Table 2). This
was confirmed after adjusting for other identified confound-
ing variables (multivariate OR 0.58 for hospital mortality,
95% CI 0.44 to 0.77 in favor of primary angioplasty) (Fig.
2). If we compared the primary angioplasty-treated group
with the t-PA-treated group, mortality was 6.4% versus
10% (univariate OR 0.62, 95% CI 0.48 to 0.80; multivariate
OR 0.61, 95% CI 0.44 to 0.83).
Primary angioplasty facilities were available at 50 (18.5%)
of 271 hospitals. At hospitals with primary angioplasty
facilities, thrombolysis was used in 58% of patients. At these
hospitals, the mortality rates were 6.6% (72/1,087) for
primary angioplasty and 11.3% (169/1,501) for thromboly-
sis (p , 0.001). At hospitals without primary angioplasty
facilities, thrombolysis was used in 96.7% of patients. The
remaining patients were treated with primary angioplasty.
Mortality was lower at hospitals with angioplasty facilities
(9.3% vs. 11.2%, p 5 0.009). This difference was no longer
significant after adjusting for the presence of angioplasty
facilities and other identified confounding variables (OR
1.15, 95% CI 0.94 to 1.42, p 5 0.1758).
In Registry patients without contraindications to throm-
bolysis and with a pre-hospital delay #12 h who did not
receive reperfusion therapy, hospital was 20.4% (1,174/5,770)
and the combined end point was 23.6% (1,364/5,770).
Analysis of different subgroups. Hospital mortality rates
in different subgroups are shown in Table 3. Primary
angioplasty was associated with lower mortality in all
subgroups. The RR showed nearly constant values of ;0.5
in favor of primary angioplasty over thrombolysis.
These differences in outcome between primary angio-
plasty and thrombolysis were confirmed by logistic regres-
sion analysis after adjusting for confounding variables (Fig.
2). Nearly all subgroups showed an independent association
between lower mortality and primary angioplasty, as could
be shown for the entire group.
We observed a significant correlation between mortality
and the absolute reduction of mortality with primary angio-
plasty (r 5 0.82, p , 0.0001) in the different subgroups: as
mortality increased, there was an increase in absolute benefit
of primary angioplasty compared with thrombolysis (Fig. 3).
Table 2. Concomitant Medications During the First 48 h After Admission and Hospital Events
Primary
Angioplasty Group
(n 5 1,327)
Thrombolysis
Group
(n 5 8,579)
p
Value OR (95% CI)
Medications
Intravenous nitroglycerin 1,125/1,326 (84.8%) 7,188/8,568 (83.9%) 0.381
Heparin 1,244/1,326 (93.8%) 7,894/8,570 (92.1%) 0.030
Aspirin 1,286/1,321 (97.4%) 8,239/8,524 (96.7%) 0.186
Beta-blockers 905/1,303 (69.5%) 5,338/8,305 (64.3%) , 0.001
ACE inhibitors 822/1,269 (64.8%) 4,555/8,161 (55.8%) , 0.001
Hospital events
Stroke 20/1,327 (1.5%) 126/8,579 (1.5%) 0.914 1.03 (0.64–1.65)
Re-infarction 31/1,327 (2.3%) 447/8,579 (5.2%) , 0.001 0.43 (0.30–0.63)
Hospital mortality 85/1,327 (6.4%) 972/8,579 (11.3%) , 0.001 0.54 (0.43–0.67)
Combined end point
(death, reinfarction, stroke)
121/1,327 (9.1%) 1,351/8,579 (15.8%) , 0.001 0.54 (0.44–0.65)
CI 5 confidence interval; OR 5 odds ratio.
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However, for the RR, no correlation with overall mortality
was found in the different subgroups (r 5 20.13, p 5 NS).
DISCUSSION
Major findings. We are presenting, for the first time,
registry data from the “real world” showing a superiority of
primary angioplasty over intravenous thrombolysis in pa-
tients eligible for thrombolysis: 6.4% mortality for primary
angioplasty versus 11.3% for thrombolysis (univariate OR
0.54, 95% CI 0.43 to 0.67; multivariate OR 0.58, 95% CI
0.44 to 0.77). This superiority was consistently observed in
all subgroups. With an increase in overall mortality for a
subgroup, the ARR of dying if treated with primary
angioplasty versus thrombolysis increased substantially, ex-
pressed by lower NNTs.
At hospitals with angioplasty facilities, primary angio-
plasty should be the method of choice for reperfusion
therapy.
Selection of type of reperfusion therapy in clinical prac-
tice. Although the decision of the type of reperfusion
therapy was left to the treating physician, multivariate
analysis showed some variables to be independently associ-
ated with a more frequent use of primary angioplasty. The
availability of angioplasty facilities was the strongest inde-
pendent predictor of the use of primary angioplasty. Nev-
ertheless, thrombolysis was used in 58% of patients at
hospitals with angioplasty facilities.
The preference for primary angioplasty in patients with a
pre-hospital delay .6 h or those in cardiogenic shock in our
registries may have been influenced by studies that sug-
gested a better outcome with primary angioplasty compared
with thrombolysis in these subgroups (21–24). For patients
with a nondiagnostic first ECG, the availability and use of
coronary angiography enable the physician to clarify the
diagnosis and may lead to a higher use of primary angio-
plasty in such patients. In patients with heart failure at
hospital admission, the potential hazard of the use of
contrast agents in such patients may have led to the
restricted use of primary angioplasty.
Primary angioplasty versus thrombolysis. Although the
characteristics of patients treated with either primary angio-
plasty or thrombolysis were different for many variables,
these differences were counterbalanced in terms of the
distribution of adverse prognostic factors. Patients present-
ing with a diagnostic first ECG were less frequently
observed in the primary angioplasty group than in the
thrombolysis group. This might be explained by a less liberal
use of thrombolysis in such patients. Tiefenbrunn et al. (11)
described the same phenomenon in the NRMI-2 data.
Mortality was not different in our patients with a diagnostic
or a nondiagnostic first ECG. Primary angioplasty showed
a favorable effect in both groups by univariate and multi-
variate analyses. Therefore, we did not exclude patients with
a nondiagnostic first ECG.
In-hospital time to treatment was longer in patients
treated with primary angioplasty than in those treated with
Figure 2. Multivariate analysis of hospital mortality for primary angioplasty and thrombolysis performed in different subgroups of patients. Adjustment was
made for age, gender, location of infarction, cardiogenic shock, previous myocardial infarction (MI), resuscitation, heart failure at hospital admission,
pre-hospital delay and type of revascularization, as well as concomitant therapy with beta-blockers and angiotensin-converting enzyme inhibitors. ECG 5
electrocardiogram.
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Table 3. Univariate Analysis of Subgroup Mortality Depending on Type of Revascularization
Variables
Mortality (%)
p Value RR NNTPrimary Angioplasty Thrombolysis
Age (yrs)
,55 10/338 (3%) 89/2,079 (4.3%) 0.2580 0.69 76
55–64 15/426 (3.5%) 176/2,410 (7.3%) 0.0050 0.48 26
65–74 31/359 (8.6%) 355/2,653 (13.4%) 0.0123 0.64 21
75–84 28/182 (15.4%) 273/1,206 (22.6%) 0.0280 0.68 14
.84 1/20 (5%) 76/222 (34.2%) 0.0269 0.15 3
Gender
Male 51/987 (5.2%) 551/6,136 (9%) 0.0001 0.58 26
Female 34/337 (10.1%) 413/2,420 (17.1%) 0.0013 0.59 14
Location of infarction
Posterior wall 43/676 (6.4%) 411/4,419 (9.3%) 0.0130 0.68 34
Anterior wall 41/596 (6.9%) 529/3,948 (13.4%) 0.0001 0.51 15
Resuscitation
No 62/1,194 (5.2%) 704/7,415 (9.5%) 0.0001 0.55 23
Yes 18/87 (20.7%) 202/570 (35.4%) 0.0076 0.58 7
Cardiogenic shock
No 57/1,214 (4.7%) 741/7,672 (9.7%) 0.0001 0.49 20
Yes 23/67 (34.3%) 165/313 (52.7%) 0.0071 0.65 5
Heart failure on admission
No 76/1,289 (5.9%) 815/8,125 (10%) 0.0001 0.59 24
Yes 9/36 (25%) 155/444 (34.9%) 0.2316 0.72 10
Bundle branch block*
None 37/437 (8.5%) 266/2,573 (10.3%) 0.2302 0.82 53
RBBB 1/18 (5.6%) 19/98 (19.4%) 0.1841 0.28 7
LBBB 1/10 (10%) 37/97 (38.1%) 0.1108 0.26 3
Previous MI
No 65/1,096 (5.9%) 772/7,362 (10.5%) 0.0001 0.57 22
$1 20/229 (8.7%) 198/1,207 (16.4%) 0.0036 0.53 13
Heart rate (beats/min)
#79 29/659 (4.4%) 348/4,360 (8%) 0.0014 0.55 28
80–99 24/402 (6%) 267/2,551 (10.5%) 0.0056 0.57 22
$100 30/222 (13.5%) 326/1,453 (22.4%) 0.0028 0.60 11
Systolic blood pressure (mm Hg)
$175 6/121 (5%) 66/914 (7.2%) 0.3610 0.69 44
150–174 15/338 (4.4%) 165/2,149 (7.7%) 0.0349 0.58 31
100–149 38/747 (5.1%) 438/4,637 (9.5%) 0.0001 0.54 23
#99 15/76 (19.7%) 181/645 (28.1%) 0.1256 0.70 12
Pre-hospital delay
,6 h 64/958 (6.7%) 684/7,209 (9.5%) 0.0049 0.70 36
6–12 h 5/168 (3%) 73/494 (14.8%) 0.0002 0.20 8
Unknown 16/201 (8%) 215/876 (24.5%) 0.0001 0.32 6
Diagnostic first ECG
No 15/259 (5.8%) 114/1,070 (10.7%) 0.0196 0.54 21
Yes 67/980 (6.8%) 812/7,055 (11.5%) 0.0001 0.59 21
Diabetes mellitus
No 60/1,043 (5.8%) 671/6,531 (10.3%) 0.0001 0.56 22
Yes 20/238 (8.4%) 235/1,454 (16.2%) 0.0024 0.52 13
Arterial hypertension
Yes 28/528 (5.3%) 289/2,830 (10.2%) 0.0005 0.52 20
No 52/753 (6.9%) 617/5,155 (12%) 0.0001 0.58 20
COPD
No 82/1,292 (6.4%) 933/8,341 (11.2%) 0.0001 0.57 21
Yes 3/33 (9.1%) 37/228 (16.2%) 0.2951 0.56 14
Renal failure
No 78/1,292 (6%) 936/8,455 (11.1%) 0.0001 0.55 20
Yes 7/33 (21.2%) 34/114 (29.8%) 0.3339 0.71 12
ACE inhibitors
Yes 22/822 (2.7%) 271/4,555 (6%) 0.0002 0.45 31
No 58/447 (13%) 635/3,606 (17.6%) 0.0146 0.73 22
Beta-blockers
Yes 26/905 (2.9%) 321/5,338 (6%) 0.0002 0.48 32
No 56/398 (14.1%) 598/2,967 (20.2%) 0.0042 0.70 16
Totals 85/1,327 (6.4%) 972/8,579 (11.3%) 0.0001 0.57 20
*Data available only from the MITRA registry.
ACE 5 angiotensin-converting enzyme; COPD 5 chronic obstructive pulmonary disease; ECG 5 electrocardiogram; LBBB 5 left bundle branch block; NNT 5 number
needed to treat; RBBB 5 right bundle branch block; RR 5 relative risk.
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thrombolysis (median 70 vs. 30 min, p , 0.001). This
40-min difference is well within the range (28 to 69 min)
reported in the published data (5,6,8,10,11).
Patients treated with primary angioplasty were more
likely to be treated with beta-blockers, compared with
patients treated with thrombolysis. The same was found for
treatment with ACE inhibitors. Hospitals with primary
angioplasty facilities always have cardiologists on call.
Treatment by specialized physicians may contribute to
better clinical results (25) because they more frequently use
recommended drug therapy.
Univariate analysis showed a superiority of primary an-
gioplasty over thrombolysis regarding in-hospital mortality.
This was confirmed by logistic regression analysis after
adjusting for patient selection and differences in concomi-
tant medications (6.4% vs. 11.3%, univariate OR 0.54, 95%
CI 0.43 to 0.67, p , 0.0001; multivariate OR 0.58, 95% CI
0.44 to 0.77, p , 0.0001). These results confirm the data of
a meta-analysis of the randomized studies (9) (4.4% mor-
tality for primary angioplasty vs. 6.5% for thrombolysis; OR
0.66, 95% CI 0.46 to 0.94, p 5 0.02), but they contrast with
the data of three registries (10–12) that showed no benefit
of primary angioplasty in clinical practice. In the MITRA
and MIR registries, mortality in patients treated with
primary angioplasty (6.4%) was similar to that of the other
studies (5.2% to 9.2%) (10–12). However, mortality in
patients treated with thrombolysis (11.3%) was higher than
that reported by the other studies (5.4% to 7.6%) (10–12).
These differences may be caused by a different method of
patient selection in these studies. Every et al. (10), the
NRMI-2 (11), as well as the randomized trials, excluded
patients in cardiogenic shock. After exclusion of patients in
shock in the MITRA and MIR registries, the mortality rate
was 4.7% for primary angioplasty and 9.7% for thrombolysis
(p , 0.0001). This 9.7% mortality rate is still higher than
those rates previously reported and may be explained by
inclusion of sicker patients in the MITRA and MIR
registries. In the MITRA and MIR studies, patients were
three years older than those in NRMI-2, and anterior wall
infarctions occurred more often. In NRMI-2, only t-PA
was used, compared with the 27.6% use of t-PA in the
MITRA and MIR registries. However, this difference in the
type of thrombolytic agent should result in only a small
difference in mortality in patients treated with thrombolysis
(26). This was confirmed by our data, which showed a
mortality rate of 10% in patients treated with t-PA, com-
pared with 11.3% for all patients treated with thrombolysis.
The difference in hospital mortality for patients treated with
primary angioplasty versus t-PA remained significant. An-
other factor that might contribute to the better outcome of
primary angioplasty in the MITRA and MIR registries
could be technical improvement over time. Thrombolysis
did not change very much in the last years of the study
period. However, primary angioplasty improved through
the introduction of concomitant medications, such as gly-
coprotein IIb/IIIa receptor inhibitors (27,28), and new
techniques, such as stents (29–31). Such an improvement in
outcome in patients with AMI treated with primary angio-
plasty, but not with thrombolysis, could be demonstrated in
another analysis of the MITRA and MIR data (32).
Analysis of subgroups. Analysis of subgroups should im-
prove our knowledge of the principle of action of primary
angioplasty compared with thrombolysis. Because of the
restricted availability of hospitals performing primary angio-
plasty, it could help us to define subgroups of patients for
whom a transfer to centers with primary angioplasty facili-
ties should be considered.
Previous studies did not examine different subgroups in a
systematic way, mainly because those studies involved small
numbers of patients. Grines et al. (6) found an advantage of
Figure 3. Relationship between overall mortality and absolute risk reduction of dying by treatment with primary angioplasty compared with thrombolysis
in the subgroups analyzed.
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primary angioplasty over thrombolysis only in high-risk
patients, but not for low-risk patients. However, Zijlstra et
al. (17) reported a reduction in the incidence of the
combined end point of death, re-infarction or stroke for
primary angioplasty compared with thrombolysis, even in
low-risk patients. Ribichini et al. (16) found a reduction in
the incidence of the combined end point in patients with
large inferior infarctions treated with primary angioplasty.
The large number of patients in the MITRA and MIR
registries made it possible to systematically analyze the
effects of primary angioplasty compared with thrombolysis
in different subgroups of patients. We found a superiority of
primary angioplasty in nearly all subgroups of patients in
univariate and multivariate analyses. Data on the presence of
bundle branch block was available only in the MITRA
registry; therefore, no logistic regression analysis was per-
formed in this subgroup. In patients with posterior AMI,
heart failure at admission, a nondiagnostic first ECG or a
previous MI, multivariate analysis did not reach statistical
significance. However, the ORs in these subgroups clearly
favored primary angioplasty and were in the same range as
those in the other subgroups. Therefore, the missing statis-
tical significance in these subgroups may be due to a lack of
power.
Our data showed that the benefit of primary angioplasty
over thrombolysis increased in those subgroups of patients
who faced an increased risk of death. This was expressed by
a strong correlation between the absolute reduction of
mortality by primary angioplasty and the overall mortality in
the different subgroups (r 5 0.82, p , 0.0001). However,
we found no decrease in the RR for primary angioplasty
versus thrombolysis with increasing mortality (correlation
between the RR of dying after primary angioplasty and
overall mortality: r 5 20.13, p 5 NS). This is shown
especially for the subgroups of patients with different heart
rates at hospital admission. Increases in heart rate were
associated with increases in mortality: #79 beats/min,
mortality 7.5%; 80 to 99 beats/min, mortality 9.9%; and
$100 beats/min, mortality 21.3%. Primary angioplasty was
associated with improved outcome in all subgroups. With
increasing mortality, the ARR of dying after primary
angioplasty increased favorably, as expressed by a decreasing
NNT (28, 22 and 11). However, the RR favoring primary
angioplasty did not change very much (0.55, 0.57 and 0.60)
(Table 5).
These data are confirmed by Holmes et al. (33), who
reported data from the GUSTO IIb study on the effect of
age on outcome with primary angioplasty versus thrombol-
ysis. They found that primary angioplasty improved out-
come better than thrombolysis. However, it did not appear
to be more beneficial in older compared with younger
patients. Thus, the incremental adverse effect of age did not
vary by treatment strategy.
Study limitations. Because MITRA and MIR are obser-
vational studies, it is not possible to totally control the
selection of patients to be treated with one of the two
therapies. We did not collect information on the rate of
technical success (residual stenosis, Thrombolysis in Myo-
cardial Infarction [TIMI] flow grade 3) of the angioplasty
procedures or the use of stents and glycoprotein IIb/IIIa
receptor inhibitors. Therefore, we were unable to control
the results for these important variables. Only a minority of
the participating hospitals had the facilities to perform
primary angioplasty. There were great differences in reper-
fusion strategies at those hospitals with primary angioplasty
facilities, as reported elsewhere (34). This fact contributes to
potential selection bias. Median in-hospital time to primary
angioplasty was 70 min in our study. Longer in-hospital
delays are associated with a worse clinical outcome (35,36).
Therefore, our data cannot be transferred to clinical settings
with exceedingly longer in-hospital delays. This analysis of
the MITRA and MIR data suffers from the limitations
faced by all registries. Therefore, it is not possible to draw
definitive conclusions regarding the mechanism responsible
for the differences in short-term outcome between primary
angioplasty and thrombolysis. However, the large number
of patients at many different centers and the uniform results
in different subgroups, which confirm the data of small,
randomized studies, strengthen the results in favor of
primary angioplasty.
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